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Abstract
Humans or mice subjected to immunosuppression, such as corticosteroids or anti-cytokine
biologic therapies, are susceptible to mucosal infections by the commensal fungus Candida
albicans. Recently it has become evident that the Th17/IL-17 axis is essential for immunity
to candidiasis, but the downstream events that control immunity to this fungus are poorly
understood. The CCAAT/Enhancer Binding Protein-β (C/EBPβ) transcription factor is
important for signaling by multiple inflammatory stimuli, including IL-17. C/EBPβ is regulated
in a variety of ways by IL-17, and controls several downstream IL-17 target genes. However,
the role of C/EBPβ in vivo is poorly understood, in part because C/EBPβ-deficient mice are
challenging to breed and work with. In this study, we sought to understand the role of C/
EBPβ in the context of an IL-17-dependent immune response, using C. albicans infection
as a model system. Confirming prior findings, we found that C/EBPβ is required for immunity
to systemic candidiasis. In contrast, C/EBPβ-/- mice were resistant to oropharyngeal candi-
diasis (OPC), in a manner indistinguishable from immunocompetent WT mice. However, C/
EBPβ-/- mice experienced more severe OPC than WT mice in the context of cortisone-
induced immunosuppression. Expression of the antimicrobial peptide β-defensin (BD)-3
correlated strongly with susceptibility in C/EBPβ-/- mice, but no other IL-17-dependent
genes were associated with susceptibility. Therefore, C/EBPβ contributes to immunity to
mucosal candidiasis during cortisone immunosuppression in a manner linked to β-defensin
3 expression, but is apparently dispensable for the IL-17-dependent response.
Introduction
Oropharyngeal candidiasis (OPC, thrush) is an opportunistic infection caused by Candida albi-
cans, a commensal fungus found in the skin and mucosal surfaces of most healthy individuals.
Host immune responses, including locally produced cytokines and antimicrobial peptides
(AMPs), prevent invasive infections by C. albicans. This microbe can also cause systemic candi-
diasis, a devastating nosocomial infection with a mortality rate of 40–80%. Most
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immunocompetent individuals maintain effective Candida-specific immunity, thereby keeping
this fungus as a commensal microbe.
Immunosuppression, particularly that affecting the T cell compartment, triggers susceptibil-
ity to pathogenic Candida infections [1, 2]. In particular, OPC is highly prevalent in HIV/
AIDS, with over 95% of HIV+ individuals experiencing at least one episode of oral thrush [3].
Immunosuppression with corticosteroids or broad spectrum antibiotics also enhances suscep-
tibility of otherwise healthy individuals to C. albicans infection. Systemic candidiasis is the
result of immunosuppression in combination with opportunistic exposure of Candida to the
bloodstream, typically through medical interventions such as catheters or abdominal surgery.
Fungal species are estimated to cause over 2 million infections per year worldwide with mortal-
ity rates in the range of 50%, yet there are no vaccines for C. albicans, or indeed any other fungi
[4]. Therefore, it is imperative to gain a better understanding the immune response to these
pathogens in order to develop more effective interventions or preventive strategies.
Recently, it has become clear that the Th17/IL-17 pathway is essential for preventing candi-
diasis [1]. In humans, nearly all C. albicans-reactive T helper cells are of the Th17 lineage [5].
Moreover, various syndromes that predispose humans to candidiasis converge on the Th17 or
IL-17 signaling pathway. For example, neutralizing autoantibodies against Th17 cytokines are
found in autoimmune polyendocrinopathy syndrome (APS-1), which is associated with
chronic mucosal candidiasis (CMC) [6]. Humans with mutations in the IL17RA gene have
been identified with CMC [7]. Similarly, mutations in ACT1, a key signaling intermediate in
the IL-17 signaling pathway, are associated with CMC [8]. Parallel findings have been made in
mice, confirming the utility of mouse models in probing underlying mechanisms of immunity
to C. albicans [9].
Despite a clear role for IL-17 in mediating immunity to candidiasis, the signaling pathways
used by IL-17 and its receptor in antifungal immune responses are poorly understood.
Although best known for its activation of pro-inflammatory signaling pathways such as NF-κB
and MAPK, IL-17 also activates transcription factors (TFs) belonging to the CCAAT/Enhancer
Binding Protein (C/EBP) family [10, 11]. Many characteristic IL-17 signature genes contain C/
EBP binding sites in their proximal promoters [12]. Moreover, C/EBPβ and C/EBPδ have been
demonstrated to be essential for regulation of specific IL-17-induced genes, such as IL-6 and
lipocalin-2 [13–15]. Regulation of C/EBPβ by IL-17 is particularly intriguing. IL-17 triggers
inducible phosphorylation of C/EBPβ, which is associated with inhibition of downstream gene
expression [13]. IL-17 also induces the alternative translation of C/EBPβ into multiple isoforms
[16]. Both of these regulatory events are mediated through a specific C-terminal subdomain of
the IL-17RA subunit [16]. To date, however, the significance of C/EBPβ in the context of IL-17
function in vivo is unclear.
C/EBPβ is expressed ubiquitously, and target gene activation by this TF varies among cell
and tissue types. Upon activation, C/EBPβ induces a variety of genes that orchestrate immune
responses, including cytokines, chemokines and their receptors. Not surprisingly, C/EBPβ-/-
mice are susceptible to numerous infections, including Listeria monocytogenes and Salmonella
typhimurium [17, 18]. Historically, C/EBPβ has been most extensively studied in the setting of
IL-1 and LPS signaling [19, 20]. In this study, we sought to understand the role of C/EBPβ in
IL-17-driven immunity, using C. albicans infection as a model system. We confirmed a previ-
ous report that C/EBPβ is essential for immunity to systemic candidiasis [21]. Surprisingly and
in contrast to IL-17R-deficient mice, C/EBPβ-/- mice were resistant to OPC. However, under
conditions of low dose cortisone-induced immunosuppression, C/EBPβ-/- mice were more sus-
ceptible to OPC. This susceptibility correlated with expression of β-defensin 3, but not with
other IL-17-dependent genes.
C/EBPβ in C. albicans Infection
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Materials and Methods
Mice
Cebpbtm1Vpo/J+/+ mice (The Jackson Laboratory, Bar Harbor ME) were bred to generate experi-
mental animals, with sample sizes based on power analyses calculated from previously pub-
lished data [9]. Genotypes were verified for all mice by PCR of ear biopsies. C57BL/6J mice
(The Jackson Laboratory) were used for cortisone titrations. All mice weighed approximately
20g and were housed under a 12 hour light/dark cycle in SPF conditions with autoclaved food
and water ad libitum. Cohorts were selected randomly and were age- and sex-matched using
both males and females at an age range of 6–10 weeks. Mice were monitored visually and
weighed at least once daily after infection. The University of Pittsburgh Institutional Animal
Care and Use Committee (IACUC) approved all animal protocols used in this study (Animal
welfare assurance number: A3187-01). All efforts were made to minimize suffering, in accor-
dance with recommendations in the Guide for the Care and Use of Laboratory Animals of the
National Institutes of Health.
Oral candidiasis
Mice were pre-swabbed orally prior to each experiment to verify the absence of pre-existing
Candida colonization. Mice were inoculated sublingually for 75 mins under anesthesia (keta-
mine 100 mg/kg and xylazine 10 mg/kg injected i.p.) with C. albicans (strain CAF2-1) placed
in an sterile saturated 0.0025 mg cotton ball, as described [22, 23]. At the end of the time course
(5 d), tongue tissue was homogenized using a Miltenyi GentleMacs Dissociator (Miltenyi Bio-
tec). Half the tissue was prepared for mRNA analysis or histology. The other half was serially
diluted and plated in triplicate on YPD agar and colony-forming units (CFU) enumerated for
tissue fungal burden determination. Mice were weighed daily. Mice were sacrificed for humane
reasons by CO2 inhalation if they lost more than 25% weight loss or exhibited signs of pain or
distress as delineated by the approved animal protocol. There were no severe adverse events in
any group.
Disseminated Candidiasis
C. albicans (strain CAF2-1) was grown overnight in YPD at 30°C. Age- and sex-matched mice
were injected in the tail vein with 1-2x105 C. albicans cells in 100ul PBS, as described [9, 24].
For injections, mice were briefly held in a commercial restraining apparatus (Braintree Scien-
tific, Braintree MA). Mice were humanely sacrificed by CO2 inhalation followed by cervical dis-
location after 10 d, weight loss exceeded 20% or when animals exhibited signs of distress such
as severe hunching, shivering or loss of righting. There were no unexpected adverse events in
any group.
Cell Culture
OKF6/TERT2 cells [25] were provided by J. Rheinwald (Brigham &Women’s Hospital, Boston
MA) cultured in Serum-Free Fibroblast media, 25 ug/ml Bovine Pituitary Extract and 2 ug/ml
EGF (Life Technologies, Grand Island NY). A heat killed (HK) extract of C. albicans (strain
CAF2-1) was prepared with ~ 4×108 yeast cells boiled for 45 mins. OKF6/TERT2 cells were
treated with 200 ng/ml IL-17 and 2ng/ml TNFα or 2×106 HK C. albicans for 24 hours.
Real-time RT-PCR
RNA from tongue was extracted with RNAeasy Kits and cDNA synthesized with a SuperScript
III First-Strand Synthesis System (Invitrogen). Gene expression was determined by qPCR with
C/EBPβ in C. albicans Infection
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PerfeCTa SYBR Green FastMix ROX (Quanta BioSciences) on a 7300 Real-Time PCR System
(Applied Biosystems), normalized to Gapdh. Primers were from Quantitect (Qiagen).
Histology
Tongue tissue was prepared for histology by the Research Histology Services core of the Uni-
versity of Pittsburgh. Samples were stained with periodic acid Schiff (PAS) or H&E and imaged
at 10–40X magnification.
Statistics
Aminimum of two replicates were performed for all experiments unless noted. Data were com-
pared by ANOVA and Mann-Whitney correction or unpaired Student’s t-test using Graphpad
Prism (v. 4). P values<0.05 were considered significant.
Results
C/EBPβ-deficient mice are susceptible to disseminated candidiasis
To evaluate the role of C/EBPβ in antifungal immunity, we subjected C/EBPβ-/- mice to dis-
seminated candidiasis, the most commonly-employed model of C. albicans infection [9]. Sys-
temic candidiasis was induced with an intravenous inoculum of 2x105 C. albicans yeast cells.
Because C/EBPβ-/- mice are on a mixed genetic background, littermates were used as controls
in these and all subsequent experiments [21]. It should be noted that C/EBPβ-/- mice are noto-
riously difficult to generate, with homozygous offspring surviving at far below expected Men-
delian ratios. Nonetheless, we were able to generate animals for experimentation, although
their numbers were of necessity lower than littermate controls. As expected, C/EBPβ-/- mice
infected intravenously with C. albicans succumbed to disease by day 4 post-infection, whereas
C/EBPβ+/+ and C/EBPβ+/- mice survived beyond day 7 (Fig 1A). These data are consistent with
documented susceptibility of the C/EBPβ-/- mice to other infections [18], and confirm pub-
lished data in systemic candidiasis [21].
C/EBPβ-deficient mice are susceptible to oral candidiasis under
conditions of immunosuppression
The most common form of candidiasis in humans occurs at mucosal surfaces, particularly in
the oral cavity. Considerable evidence supports a vital role for IL-17 in immunity to OPC [26],
and IL-17 induces downstream signals in part through C/EBPβ [13, 14]. Therefore, to deter-
mine the extent to which C/EBPβ-dependent pathways drive immunity to OPC, we subjected
C/EBPβ-/- mice to OPC. In the standard mouse model of OPC, WT mice are resistant to infec-
tion, clearing the fungus within 4–5 days and exhibiting no overt symptoms of thrush. In con-
trast, mice subjected to high dose cortisone exhibit severe OPC symptoms, including weight
loss, visible fungal lesions on the tongue and buccal mucosa, and a high fungal load determined
by CFU assessment of homogenized tongue tissue plated on YPD agar [27]. The control mice
behaved as expected, with C/EBPβ+/+ and C/EBPβ+/- mice fully clearing C. albicans from the
oral cavity by day 5 post infection. High-dose cortisone treatment (225 mg/kg) caused severe
susceptibility to OPC, with fungal loads averaging 1.2x106 CFU/g. Unexpectedly, C/EBPβ-/-
mice were fully resistant to infection, exhibiting weight loss profiles and oral CFU levels similar
to C/EBPβ+/+ and C/EBPβ+/- control mice, in the range of 1–5 CFU/g tongue tissue (Fig 1B and
1C). Therefore, OPC is to our knowledge the first infection to which C/EBPβ-/- mice are resis-
tant. In contrast, we previously showed that IL-17RA-/-, IL-17RC-/- and Act1-/- mice are
C/EBPβ in C. albicans Infection
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susceptible to OPC [23, 28, 29]; therefore, these data further demonstrate that C/EBPβ appears
to be dispensable for an effective IL-17-dependent immune response.
Since the C/EBPβ-/- mice did not develop OPC upon infection with C. albicans, a plausible
alternative hypothesis was that they might instead exhibit enhanced resistance to infection.
Indeed, C/EBPβ has been linked to inhibition of IL-17-mediated signal transduction in vitro in
several prior studies [13, 16]. However, to address this question, we needed to establish a
Fig 1. C/EBPβ-/- mice exhibit increased susceptibility to systemic candidiasis but are resistant to oral
candidiasis. (A) The indicated mice (n = 3 per group) were injected with C. albicans in the lateral tail vein.
Time to sacrifice is indicated (days). *P<0.05 versus (vs) C/EBPβ+/- mice using Log-rank (Mantel-Cox). (B)
The indicated mice were infected sublingually withC. albicans for 75 mins. After 5 d, fungal loads in tongue
were assessed by CFU enumeration of tongue tissue homogenates. Bars indicate geometric mean with 95%
CI. C/EBPβ+/+ SHAM (n = 3), C/EBPβ+/+ (n = 5), C/EBPβ+/- (n = 9), C/EBPβ-/- (n = 3), C/EBPβ+/+ plus 225mg/
kg cortisone (n = 3); cortisone acetate was administered by subcutaneous injection on days -1, +1 and +2
relative to infection. P<0.05 by t-test with Mann-Whitney correction: * vs C/EBPβ+/+ WT, 6¼ vs C/EBPβ+/-, # vs
C/EBPβ-/-, π vs C/EBPβ+/+ 225mg/kg. C. Weights of mice were assessed daily and graphed as percent of
starting weight. * vs C/EBPβ+/+ WT. P<0.05 by t-test with Mann-Whitney correction. Experiment was
performed once.
doi:10.1371/journal.pone.0136538.g001
C/EBPβ in C. albicans Infection
PLOS ONE | DOI:10.1371/journal.pone.0136538 August 28, 2015 5 / 14
model system in which WTmice exhibited a mild degree of disease so that we could observe
enhanced resistance to OPC. Accordingly, WT mice were treated with graded doses of corti-
sone acetate and infected orally with C. albicans. This regimen resulted in a dose-dependent
susceptibility to OPC (Fig 2A). Based on these data, we selected 60 mg/kg as an appropriate
Fig 2. C/EBPβ-/- mice exhibit increased susceptibility to oral candidiasis in the context of cortisone-
induced immunosuppression. (A) C65BL/6 mice (“WT”) were treated with the indicated doses of cortisone
acetate at days -1, +1 and +2 relative to infection. After 5 d, fungal loads in tongue were assessed by CFU
enumeration of tongue tissue homogenates. SHAM (n = 3), No cortisone control (n = 5), 60mg/kg (n = 9), 120/
112mg/kg (n = 8), and 225mg/kg (n = 8). Data are pooled from 2 independent experiments. Bars indicate
geometric mean with 95% CI. P<0.05 by t-test with Mann-Whitney correction: * vs NO CORT, 6¼ vs 60mg/kg,
# vs 120/112mg/kg and π vs 225mg/kg. (B) The indicated mice were infected orally as described in panel A.
Cortisone acetate was administered subcutaneously on days -1, +1 and +2 relative to infection. C/EBPβ+/+
SHAM (n = 3), C/EBPβ+/+ (n = 5), C/EBPβ+/+ 60 mg/kg (n = 16), C/EBPβ+/- 60mg/kg (n = 16), C/EBPβ-/- 60mg/
kg (n = 10) and C/EBPβ+/+ 225mg/kg (n = 4). P<0.05 by t-test with Mann-Whitney correction: * vs C/EBPβ+/+
NO CORT, 6¼ vs C/EBPβ+/+ 60mg/kg, # vs C/EBPβ+/- 60mg/kg and π vs C/EBPβ-/- 60mg/kg. Data are pooled
from two independent experiments. C. Representative tongue sections from the indicated mice were stained
with H&E or Periodic-acid Schiff (PAS). Scale bar indicates 200 μM.White arrows indicate hyphae.
doi:10.1371/journal.pone.0136538.g002
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concentration, as mice given this dose exhibited an average of 89 CFU/g tongue. Accordingly,
C/EBPβ-/- or control mice were subjected to OPC in combination with 60 mg/kg cortisone ace-
tate. As shown, C/EBPβ-/- mice given 60 mg/kg cortisone showed an average CFU of 11,395
CFU/g, which was significantly greater than fungal loads in the C/EBPβ+/+ and C/EBPβ+/- mice
given cortisone (average loads = 271 and 203 CFU/g, respectively) (Fig 2B). As expected, high
dose cortisone (225 mg/kg) caused even higher fungal burdens (6x105 CFU/g). Invasive hyphae
were observed in PAS-stained tongue sections from C/EBPβ-/- mice but not in controls (Fig
2C). These data indicate that C/EBPβ contributes to immunity to OPC, but only under condi-
tions of cortisone-mediated immunosuppression.
Mechanisms of C/EBPβ-mediated immunity to OPC
In order to understand the mechanisms by which C/EBPβ contributes to immunity to OPC, we
evaluated expression of genes previously shown to be induced in immunocompetent mice dur-
ing oral infection with C. albicans [23, 30]. To that end, we measured mRNA levels of chemo-
kines, cytokines anti-microbial peptides and TFs in the oral mucosa (tongues) of mice
subjected to OPC, measured at day 5. We were specifically seeking genes that showed an
impairment in C/EBPβ-/- mice compared to controls. Somewhat surprisingly, expression of
most genes was not impaired in infected C/EBPβ-/- mice; in fact, in many instances, transcripts
were expressed at higher levels compared to controls (Fig 3, Table 1). These genes included
chemokines (Cxcl1, Cxcl2, Cxcl5, Fig 3A), cytokines (Il6, Csf3, Il17a, Il22, Fig 3B), antimicrobial
peptides (Lcn2, S100a8, Fig 3C) and immunoregulatory transcription factors (Nfkbiz, Cepbd,
Fig 3D). The elevated expression of these factors in C/EBPβ-/- mice was somewhat unexpected,
but probably reflects the increased fungal burden in the mice at this time point with a concomi-
tant active immune response.
In contrast to the aforementioned genes, the expression of Defb3 did correlate with suscepti-
bility to OPC, as expression was much lower in C/EBPβ-/- mice compared to littermate controls
(Fig 4A). Defb3 encodes the antimicrobial peptide β-defensin 3 (BD3), which is the accepted
murine homologue of human BD2. BD3 expression has been previously linked to IL-17-immu-
nity to OPC, and this AMP also has intrinsic, direct candidacidal activity [23, 30, 31]. In light
of this observation, we also assessed the expression of Defb3 in non-immunosuppressed set-
tings. Although Defb3 was induced in C/EBPβ+/+ and C/EBPβ+/- mice, expression was impaired
in C/EBPβ-/- animals (Fig 4B). However, overall expression was notably lower than in corti-
sone-treated mice (Fig 4A and 4B). Therefore, impaired Defb3 expression correlates with C/
EBPβ-deficiency in cortisone-induced susceptibility to OPC, and may account for the increased
fungal burdens seen in these conditions.
Based on this observation, we assessed other members of the β-defensin family that have
been linked to candidiasis, namely Defb1 and Defb4 [32–35]. However, neither showed the cor-
relative link to C/EBPβ-mediated disease susceptibility that was seen for Defb3 (Fig 4A). We
also assessed Defb2, but expression was undetected in this tissue (data not shown). Modest
changes were also seen for these genes in non-immunosuppressed conditions (Fig 4B), but
these differences were so slight we think it unlikely that they contribute to the susceptible
phenotype.
Finally, to determine whether the impact of C/EBPβ could be isolated to oral epithelial tis-
sue, we asked whether C. albicans exposure could induce this defensin directly in oral keratino-
cytes. There is a paucity of tractable murine oral epithelial cell systems in which to assess this
issue, so instead we used the human OKF6/TERT2 oral keratinocyte cell line [25]. Cells were
cultured for 24 with a heat-killed (HK) C. albicans cell extract [30]or with inflammatory cyto-
kines (IL-17+ TNFα) as a positive control. We assessed expression of DEFB4A, which encodes
C/EBPβ in C. albicans Infection
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Fig 3. The susceptibility of C/EBPβ-/- mice to OPC does not correlate with expression of prototypical IL-17-regulated genes.mRNA from tongue was
isolated from the indicated mice 5 days after oralC. albicans infection [C/EBPβ+/+ SHAM (n = 3), C/EBPβ+/+ NO CORT (n = 3), C/EBPβ+/+ 60mg/kg (n = 5), C/
EBPβ+/- 60mg/kg (n = 6), and C/EBPβ-/- 60mg/kg (n = 5)]. Complementary DNA was prepared and subjected to qPCR analysis to detect the indicated genes.
Results are presented as fold induction over SHAM treated mice and normalized to expression ofGapdh. Data are pooled from 2 independent experiments.
P<0.05 by student unpaired t-test: * vs C/EBPβ+/+ NO CORT, 6¼ vs C/EBPβ+/+ 60mg/kg, # vs C/EBPβ+/- 60mg/kg and π vs C/EBPβ-/- 60mg/kg.
doi:10.1371/journal.pone.0136538.g003
C/EBPβ in C. albicans Infection
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BD2, the human orthologue of murine BD3. Whereas cytokines induced substantial expression
of DEFB4A, there was no detectable induction of this gene upon C. albicans treatment, which
held true at both early and late time points (Fig 4C, data not shown).
Discussion
Since IL-17 is a key regulator of immunity to oral candidiasis and mediates gene regulation
through C/EBPβ, the impetus for this study was to understand possible connections between
IL-17 signaling, C/EBPβ and antifungal immunity. The C/EBP transcription factors are central
regulators of immune responses, controlling expression of a myriad of cytokines, receptors and
other genes important in host defense against infection [20]. C/EBPβ [also known as liver acti-
vated protein (LAP) or nuclear factor inducing IL-6 (NF-IL6)] is an intronless gene that was
among the first TFs to be characterized, yet is surprisingly poorly understood in the context of
mammalian immunity. In part this deficit is due to the early lethality of C/EBPβ-/- mice. C/
EBPβ-/- animals often die shortly after birth, an effect that is more pronounced in non-SPF
conditions [21]. These mice exhibit lymphoproliferative and myeloproliferative disorders and
have high circulating levels of IL-6 [18]. Not surprisingly, C/EBPβ-/- mice are highly sensitive
to many pathogens, including Listeria monocytogenes, Salmonella typhimurium as well as sys-
temic C. albicans (Fig 1A) [18, 21].
C/EBPβ is subject to numerous forms of post-transcriptional and post-translational modifi-
cations, many of which are regulated by inflammatory stimuli such as LPS, IL-1 and IL-17. For
example, C/EBPβ undergoes alternative translation into three functionally distinct isoforms,
with IL-17 enhancing expression of the LAP and liver inhibitory protein (LIP) isoforms relative
Table 1. (Simpson-Abelson et al.).
Gene Protein C/EBPβ Genotype
+/+ +/- -/-
Il6 IL-6 - - ***
Il17a IL-17A **** **** ****
Il22 IL-22 *** *** ****
Il23 IL-23p19 - - *
Csf2 G-CSF - * *
Ifng IFNγ - - -
Cxcl1 CXCL1/KC - * ***
Cxcl2 CXCL2 * *** ****
Cxcl5 CXCL5 * *** ****
Ccl20 CCL20 **** **** ****
S100a9 S100A9 **** **** ****
Lcn2 Lipocalin-2/24p3 * * ***
Defb3 β-defensin 3 *** *** **
Nfkbiz IκBζ * * **
Cebpd C/EBPδ - - -
Transcript expression levels of the indicated genes in tongues isolated from the indicated mice 5 days after
induction of oropharyngeal candidiasis. Increase over Sham-infected mice is indicated as follows:
*2-4-fold,
** 5–10 fold,
*** 10–50 fold,
**** > 100-fold
doi:10.1371/journal.pone.0136538.t001
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to the normally dominant LAP isoform [16, 36]. IL-17 also induces phosphorylation of C/EBPβ
on sites that are known to regulate its transcriptional capacity [13, 37]. Given these connections,
we were surprised to observe that C/EBPβ-deficient mice were fully resistant to OPC, at least in
the absence of underlying immunosuppressive drugs. In fact, as far as we know, OPC is the only
infectious disease to which these mice have been found to be resistant (Fig 1B).
Fig 4. Susceptibility of C/EBPβ-/- mice to OPC correlates with expression of BD3. (A)mRNA from tongue was isolated from the indicated mice 5 days
after oral C. albicans infection [C/EBPβ+/+ SHAM (n = 3), C/EBPβ+/+ NO CORT (n = 3), C/EBPβ+/+ 60mg/kg (n = 5), C/EBPβ+/- 60mg/kg (n = 6), and C/EBPβ-/-
60mg/kg (n = 5)]. Complementary DNA was prepared and subjected to qPCR analysis to detect the indicated genes. Results are presented as fold induction
over SHAM treated mice and normalized to expression ofGapdh. Data are pooled from two independent experiments. P<0.05 by student unpaired t-test. * vs
C/EBPβ+/+ NO CORT, 6¼ vs C/EBPβ+/+ 60mg/kg, # vs C/EBPβ+/- 60mg/kg and π vs C/EBPβ-/- 60mg/kg. (B)mRNA from tongue was isolated from the
indicated mice 5 days after oralC. albicans infection and analyzed as in panel A. C/EBPβ+/+ SHAM (n = 3), C/EBPβ+/+ (n = 2), C/EBPβ+/- (n = 2), and C/
EBPβ-/- (n = 2). Data are from one experiment. * P<0.05 by student unpaired t-test. vs C/EBPβ+/+, 6¼ vs C/EBPβ+/- and π vs C/EBPβ-/-. (C)OKF6/TERT2
human oral keratinocytes were treated with 200 ng/ml IL-17 plus 2ng/ml TNFα or with 2×106 HKC. albicans for 24 h. Complementary DNA was prepared and
subjected to qPCR analysis to detect DEFB4A. Data are normalized to expression ofGAPDH and represent absolute levels. Data are representative of 2
independent experiments. *P<0.05 compared to unstimulated OKF6/TERT2 cells.
doi:10.1371/journal.pone.0136538.g004
C/EBPβ in C. albicans Infection
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IL-17 deficiency causes mucosal candidiasis in humans with rare genetic defects in this
pathway [38]. However, a much more common risk factor for OPC in the general population
is the use of immunosuppressive drugs, including systemic or inhaled corticosteroids. Exactly
why this is the case is poorly understood at the molecular level, but our data suggest that C/
EBPβ is an important component of oral immunity in this context. The gene encoding
CEBPβ is upregulated in human epithelial and endothelial cells in response to Candida expo-
sure as well as in samples from women with vaginal candidiasis [39]. Moreover, our data
imply that this susceptibility is not due to a failure of IL-17 signaling, since C/EBPβ-/- mice
are resistant to OPC, whereas mice with impaired IL-17 signaling capability (e.g., IL-17RA-/-,
IL-17RC-/-, Act1-/- or RORγt-/- mice) are all highly susceptible [23, 28, 29, 40]. Notably, IL-
17R-deficient mice have significantly lower oral fungal burdens of C. albicans than mice
given high dose corticosteroids [23], indicating that C/EBPβ appears to contribute to the
non-IL-17-dependent arm of antifungal immunity. One mechanism by which C/EBPβ con-
tributes to cortisone-induced OPC may be in regulating the monocyte/macrophage lineage.
C/EBPβ is potently induced by LPS and TNFα in these cells, where it regulates a myriad of
genes controlling proliferation, differentiation and function of these innate cells [41]. Consis-
tently, depletion of monocytes and neutrophils induces severe OPC in mice, with fungal
loads similar to cortisone-treated animals and several logs higher than IL-17RA-deficient
mice [42].
Our data suggest a link between C/EBPβ and Defb3 gene expression in OPC, but not other
classic IL-17 target genes that are regulated by C/EBPβ such as Il6 or Lcn2 [12] (Table 1, Fig
4). Indeed, neither IL-6-/- nor Lcn2-/- mice are susceptible to OPC [29, 40], which is consis-
tent with the resistance of C/EBPβ-/- mice to this disease. In this regard, β-defensins are well
established as regulators of immunity to C. albicans and other mucosal pathogens [43]. BD3
and its human orthologue BD2 are expressed in oral mucosa during exposure to C. albicans
[23, 30, 44–46]. Upregulation of BD2 in lung epithelial cells is regulated by IL-17 and other
cytokines through the NF-κB and PI3K pathways [47–49]. It is likely that similar pathways
are operative in oral epithelium as well. In addition to its activity as an antimicrobial peptide,
BD3 is also a ligand for the chemokine receptor CCR6, which is expressed on various muco-
sal lymphocytes including IL-17-expressing cells [31, 50]. We speculate that both activities
are operational in the setting of OPC, but of course further experimentation in this regard is
warranted.
A complete profile of genes regulated by C/EBPβ during cortisone-induced OPC would
require a global analysis such as ChIP-Seq, which would be technically challenging since it is
difficult to purify enough viable oral epithelial cells from tongue to accomplish such a study
[23, 51]. This is especially true following steroid use, which depletes hematopoietic cell num-
bers. In attempting to identify a system where a more molecular approach might be accom-
plished, we analyzed a human oral keratinocyte cell line, OKF6/TERT2 [25] for the ability to
induce BD2 (Fig 4C). Although the gene encoding BD2 was induced in response to inflamma-
tory cytokines (IL-17 and TNFα), treatment with a heat-killed C. albicans extract alone did not
induce this defensin. Since the impact of C/EBPβ deficiency seems to be largely independent of
IL-17, this system is not suitable for understanding how BD2 (and by extension, BD3) is regu-
lated by C/EBPβ in this setting.
In summary, these data shed new light on how immunity to mucosal candidiasis is con-
trolled, and also the contribution of C/EBPβ to steroid-induced fungal susceptiblity. Defensins
may therefore be an attractive therapeutic target in treating mucosal fungal infections associ-
ated with immunosuppression.
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